SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck’s Healthcare business sector

SpringWorks立即为默克的医疗保健业务部门增加收入并加速中长期增长。

Merck, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.

默克公司，一家领先的科技公司，今天宣布已完成以 34 亿美元（约 30 亿欧元）* 的企业价值收购 SpringWorks Therapeutics, Inc.，此前已获得监管批准并满足其他惯例交割条件。

*Based on SpringWorks’ cash balance as of 31 December, 2024

*基于SpringWorks截至2024年12月31日的现金余额

The definitive agreement between Merck and SpringWorks, based in Stamford, Connecticut, was

总部位于康涅狄格州斯坦福德的默克公司与斯普林伍兹公司之间的最终协议是

announced on 28 April, 2025

2025年4月28日宣布

. It represents one of the biggest M&A deals in the global biopharma sector so far in 2025. The business combination will immediately contribute to Merck’s revenues and is expected to be accretive to the company’s earnings per share pre (EPS pre) by 2027.

它是2025年迄今为止全球生物制药领域最大的并购交易之一。此次业务合并将立即为默克公司带来收入，并有望在2027年前提升公司每股收益（EPS pre）。

“Today, we officially welcome SpringWorks to Merck. The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck as a globally diversified science and technology powerhouse,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “This is the largest acquisition we have made for our Healthcare business sector in nearly 20 years, marking an exciting new chapter for Healthcare.

“今天，我们正式欢迎SpringWorks加入默克公司。收购SpringWorks展示了我们果断的投资组合策略，进一步巩固默克作为全球多元化科技巨头的地位，”默克公司执行董事会主席兼首席执行官贝伦·加里奥表示。“这是近20年来我们为医疗保健业务领域进行的最大规模收购，标志着医疗保健领域令人振奋的新篇章。”

Furthermore, we remain committed to identifying M&A opportunities across our three business sectors, with a focus on Life Science, prioritizing strategic fit, financial robustness, and long-term value creation.”.

此外，我们仍将致力于在三大业务领域中寻找并购机会，重点关注生命科学领域，优先考虑战略契合度、财务稳健性和长期价值创造。

“This acquisition is a significant step forward in bringing innovation to patients living with rare and often debilitating tumors—many of whom are young and facing a long, uncertain journey with limited treatment options,” said Danny Bar-Zohar, CEO of Healthcare and member of the Executive Board at Merck.

“此次收购是为患有罕见且常常令人虚弱的肿瘤患者带来创新的重要一步——其中许多患者都很年轻，面临着漫长而不确定的旅程，且治疗选择有限，”默克公司医疗保健部门首席执行官兼执行董事会成员丹尼·巴尔-佐哈尔表示。

“By combining our global reach with SpringWorks’ expertise, we are expanding access to life-changing therapies for patients around the world. At the same time, this move strengthens our foundation for further expansion in rare tumors and adjacent disease areas. I’d like to warmly welcome the SpringWorks team to Merck.”.

“通过将我们的全球影响力与SpringWorks的专业知识相结合，我们正在扩大世界各地患者获得改变生命疗法的机会。同时，此举加强了我们在罕见肿瘤及相邻疾病领域进一步扩展的基础。我谨代表默克公司，热烈欢迎SpringWorks团队的加入。”

SpringWorks’ portfolio features two highly innovative products for the treatment of rare tumors in areas of high unmet need where limited treatment options exist. U.S. Food and Drug Administration (FDA)-approved, OGSIVEO

SpringWorks的产品组合包含两款针对未满足需求高且治疗选择有限的罕见肿瘤的高度创新产品。已获美国食品药品监督管理局（FDA）批准，OGSIVEO

(nirogacestat) is a first-in-class therapy for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. In June 2025, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of nirogacestat..

(nirogacestat) 是一种首创的疗法，用于治疗需要系统性治疗的进展性硬纤维瘤成人患者。2025年6月，欧洲药品管理局（EMA）人用药品委员会（CHMP）采纳了推荐批准nirogacestat的积极意见。

GOMEKLI™ (mirdametinib) is the first and only FDA-approved therapy for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. In May 2025, the CHMP adopted a positive opinion recommending the approval of mirdametinib..

GOMEKLI™（米达美替尼）是首个也是唯一获得FDA批准的疗法，用于治疗2岁及以上患有1型神经纤维瘤病（NF1）且伴有无法完全切除的症状性丛状神经纤维瘤（PN）的成人和儿童患者。2025年5月，CHMP采纳了推荐批准米达美替尼的积极意见。

SpringWorks’ portfolio complements Merck’s progress in building a rare tumor business with Merck having worldwide commercialization rights for pimicotinib, an investigational therapy developed by Abbisko Therapeutics Co., Ltd. for patients with tenosynovial giant cell tumor (TGCT). Global regulatory filings for pimicotinib are underway.

SpringWorks的产品组合补充了默克在建立罕见肿瘤业务方面的进展，默克拥有由上海拓臻生物技术有限公司开发的、用于治疗腱鞘巨细胞瘤（TGCT）患者的在研药物pimicotinib的全球商业化权利。Pimicotinib的全球监管文件正在筹备中。

The joint portfolio will serve a broad range of patients with rare tumors who have high unmet medical needs..

联合产品组合将服务于有高度未满足医疗需求的罕见肿瘤患者。

Shares in SpringWorks will no longer be traded on the Nasdaq, with Merck now being the sole owner of SpringWorks. SpringWorks shareholders are being paid US$ 47 per share in cash.

SpringWorks的股票将不再于纳斯达克交易，默克现已成为SpringWorks的唯一所有者。SpringWorks的股东每股将获得47美元的现金补偿。